CAR T-cell therapy for hard-to-control NMOSD
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests an experimental cell therapy (BAFFR CAR T cells) for people with neuromyelitis optica spectrum disorder (NMOSD) who have not responded well to standard treatments. It aims to see if these cells can help reduce relapses and improve symptoms by targeting a specific immune cell receptor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 60 years old.
- You have NMOSD that is positive for a protein called AQP4-IgG.
- You have taken at least one immunosuppressant medicine for more than a year but your symptoms are still not well-controlled.
- You have had at least 2 relapses (flare-ups) in the last 12 months, or at least 3 in the last 2 years with one in the last year.
- You are willing to use effective birth control for one year after the cell infusion (if you or your partner could become pregnant).
- You do not have certain active infections (like hepatitis B or C, HIV, CMV, or syphilis) or B cell deletion treatment within the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called C-CAR168 for people with certain autoimmune diseases that have not improved with standard therapies. It aims to see if this treatment can help control the disease.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a special immune cell therapy (CAR-T) for people with a type of NMOSD that hasn't responded well to other treatments. The cells are made to target a protein called BCMA to help calm the immune attack on your nerves.
This early-stage trial tests a new type of immune cell therapy (CAR T-cells) against several relapsed or hard-to-treat autoimmune diseases that affect the nervous system. The goal is to see if this treatment can safely calm the immune system and improve symptoms.
This trial tests a new treatment using your own immune cells (called BAFF-R CAR T cells) for people with severe nerve and immune diseases that have not improved with standard medicines. These cells are designed to target and destroy certain immune cells that may be causing your illness.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
Hear when a new Neuromyelitis Optica Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.